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Colony-stimulating factor 2 receptor beta (CSF2RB) is the shared beta-chain receptor and essential signaling component for IL-3, IL-5 and GM-CSF receptor activation. In the context of GM-CSF signaling, the ligand-specific alpha chain (CSF2RA) complexes with CSF2RB and GM-CSF ligand, forming a dodecameric complex in which the proximity of CSF2RB subunits allows associated JAK2 kinases to transphosphorylate.
1 CSF2RB signals through several pathways including JAK2/STAT5, PI3K/mTOR and MEK/ERK to promote survival, proliferation and differentiation (reviewed in Hercus et al. ). Both spontaneous transformation 3, 4 and random mutagenesis 4, 5 screens have shown that CSF2RB mutations can result in ligand-independent activation in vitro. However, these predicted oncogenic mutations have never been observed clinically. In fact, the only phenotypic CSF2RB mutations reported are recessive, loss-of-function, germline mutations in pulmonary alveolar proteinosis. 6 As oncology moves toward an age of personalized and molecularly targeted treatment it will require the identification and in vitro characterization of targetable genetic lesions. Here we describe the first case of a leukemia patient harboring a germline, CSF2RB-activating point mutation (R461C) and identify small-molecule inhibitors with therapeutic potential against this mutation.
We obtained a pediatric T-cell acute lymphoblastic leukemia (T-ALL, Supplementary Figure 1a ) with informed consent approved by the Institutional Review Boards of Oregon Health & Science University and Erasmus University Medical Center, Sophia Children's Hospital. We isolated mononuclear cells and performed deep sequencing as previously described, 7 uncovering the CSF2RB R461C mutation at a 54% allele burden (Supplementary Figures 1b and c) . The patient also presented with somatic NOTCH1-truncation, NOTCH1 missense and PTEN point mutations, which are all recurrent and leukemiaassociated mutations 8 (other observed mutations in Supplementary  Table 1 ). R461C was later confirmed by Sanger sequencing as a heterozygous, germline variant using a minimal residual disease day 79 sample for normal DNA (Supplementary Figure 1d) . CSF2RB R461C has never been previously described in cancer patients (including public databases) but is listed as a SNP in the 1000 Genomes database 9 (rs371045078) at a low-allele frequency (MAF = 0.000998, 5 observations in 1000 Genomes; 9 MAF = 0.000272, 33 observations in the Exome Aggregation Consortium 10 ) in exclusively heterozygous cases. Prior work has established that cancerpredisposing mutations exist in the germline of healthy individuals at frequencies as high as 1.1%, but those frequencies elevate to over 8% in children and adolescents with cancer, most of which demonstrate no family history of cancer. 11 Congenital mutations in CSF3R have also been observed to precede the development of acute myeloid leukemia. 12 In addition, there are numerous reports of families with gain-of-function germline mutations in receptors with similar biology as CSF2RB (for example, CSF3R, 13 EPOR 14 and MPL 15 ) and in many of these pedigrees the affected family members do not develop overt leukemia, though they sometimes exhibit elevated blood counts.
The location of this variant, within the putative membranespanning portion of the receptor, is of particular interest as this region is a hot spot for activating mutations in vitro. 5 Previously, mutations altering the number of membrane-spanning or membraneadjacent unpaired cysteines have been shown to activate the IL-7 receptor in T-ALL 16 and RET in medullary thyroid carcinoma. 17 CSF2RB has been shown to be partially activated in vitro by replacement of the extracellular domain with a short, cysteine-containing sequence. 4 Last, multiple sequence alignment of CSF2RB homologues demonstrated that arginine 461 is conserved across most mammals (Supplementary Figure 2) increasing the potential that R461C could have functional relevance and cooperate with canonical leukemogenic mutations. Accordingly, we hypothesized that R461C could activate CSF2RB-signaling and contribute to the patient's leukemia.
We cloned CSF2RB R461C into the pMXs-IRES-Puro plasmid and transfected into IL-3-dependent murine Ba/F3 cells by electroporation. Stably transfected cells were selected using two weeks of continual 2 μg/ml puromycin selection prior to performing IL-3 withdrawal transformation assays as previously described.
7 R461C conferred factor-independent growth while wild-type (WT) CSF2RB did not ( Figure 1a, Supplementary Figure 3 ). The full CSF2RB transgene was sequence confirmed in two biologically replicate, IL-3 independent cell lines and used for further studies.
We identified that CSF2RB R461C expression resulted in an accumulation of surface CSF2RB protein, relative to WT, prior to IL-3 withdrawal when assayed by flow cytometry (Supplementary Figure 4) . Furthermore, immunoblot analysis showed that the R461C protein is significantly increased in IL-3-independent cells relative to WT cells grown in IL-3 ( Figure 1b , details and all antibodies included in Supplementary Methods and Supplementary Table 2 ). As both exogenous versions of CSF2RB were expressed by identical promoters we rationalized that the accumulation was due to changes in CSF2RB protein stability. We performed time course experiments using 100 µg/ml cycloheximide in dimethyl sulfoxide followed by staining with PE-conjugated anti-CSF2RB to determine alterations in surface protein stability. The R461C mutant possessed a prolonged surface half-life relative to WT CSF2RB (6.5 vs 3.6 h; Figure 1c ). Given the presence of a novel cysteine and increased stability in the R461C mutant, we investigated disulfide-linked receptor oligomerization by immunoblot under nonreducing conditions. Comparing the WT-and R461C-expressing cells, we observed CSF2RB-containing complexes of~500 kDa that showed a reduced intensity when 2-mercaptoethanol was added to the lysate (normally CSF2RB runs at 125 kDa, Figure 1d Previous studies have shown that mutations within receptor transmembrane domains can result in constitutive receptor oligomerization and activation. [15] [16] [17] The role of the CSF2RB transmembrane domain in receptor stability and signal transduction has not been characterized. 1 Even the boundaries of the membrane-spanning region have not been empirically studied, though it is commonly assumed to span residues 444-460 based on early domain modeling. 5 Various modern models consistently predict a much larger domain (Supplementary Figure 5) , including residue 461, suggesting R461C might be within the transmembrane domain and alter receptor-receptor interactions. Another possibility is that the loss of a charged residue near the membrane boundary could result in shifting or fluidity of the transmembrane domain of the mutant receptor.
Using immunoblot and co-immunoprecipitation analysis, we showed that transformed Ba/F3 cells expressing CSF2RB R461C exhibited constitutive receptor phosphorylation and signaled through several pathways, including STAT5, PI3K/mTOR1 and MEK/ERK (Figures 2a and b) . To identify therapeutically targetable pathways we utilized a 104 small-molecule inhibitor library screen, as previously described, Table 3) . These treatments were specific and cytotoxic, inducing apoptosis in R461C-expressing cells (Figure 2d and Supplementary Figure 6D ). Although these inhibitors have a differential specificity for targeting JAK kinases (Tofacitinib: JAK2/3, Ruxolitinib: JAK1/2, AZD1480: JAK2), the strongest target is JAK2. We also observed reduced levels of total JAK2 in R461C cells (Figure 2b) , which is consistent with JAK2 activation and then degradation through a STAT5/SOCS-1 negativefeedback loop. 19 These results suggest a dependency on the JAK/ STAT pathway that is consistent with ligand-independent activation of CSF2RB in R461C-expressing cells. Targeted inhibition of JAK2 using AZD1480 quickly reduced levels of phosphorylated STAT5, validating the specific nature of the inhibition and highlighting JAK2 as the key mediator of CSF2RB R461C signaling (Figure 2e) .
On sequencing 449 primary hematopoietic malignancies, we found seven additional CSF2RB mutations (Supplementary Table 4 ) but none were membrane spanning and all seven were incapable of transforming Ba/F3 cells (data not shown). Several other CSF2RB-activating mutations have been observed in vitro, but have not been observed in primary patient samples. CSF2RB R461C is a rare germline variant and recent studies of germline cancer-predisposing mutations have not included CSF2RB, 11 possibly because of the lack of previous evidence showing the oncogenic potential of CSF2RB. Our data would support the inclusion of CSF2RB in future studies. CSF2RB R461C is a transforming mutation in vitro, and further investigation is necessary to determine its status as a predisposing or cooperative congenital mutation.
CSF2RB has previously been shown to become factorindependent through in vitro mutagenesis screens. One such screen successfully predicted R461C to be an active variant 5 (though insufficient to transform Ba/F3 cells in a short-term withdrawal assay), demonstrating the potential for predictive Letters to the Editor mutagenesis screens. In spite of this in vitro evidence, there has never before been a reported case of cancer with a CSF2RB-activating mutation. We have demonstrated for the first time that a targetable CSF2RB variant found in a human leukemia confers factor-independent growth, receptor phosphorylation and accumulation, and constitutive JAK/STAT pathway activation. Our findings contribute to ongoing efforts to identify potential germline predisposition mutations in pediatric cancers, and are consistent with observations that genetic alterations activating cytokine receptor pathways are common in leukemia. Our research highlights the need for basic research to investigate and characterize the functional role of the CSF2RB transmembrane domain in signaling and recycling of the receptor. Finally, JAK inhibitors blocked the growth of R461C-transformed cells, thereby providing a therapeutic rationale to consider JAK inhibitors in any future cases of CSF2RB-activated leukemias. 
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